BreatheSuite Adds Brad Fluegel to its Board

Brad Fluegel has joined BreatheSuite Inc.’s Board of Directors.
 
“We welcome Brad to the BreatheSuite Board of Directors and look forward to leveraging his knowledge and experience in digital health as we continue to expand the BreatheSuite program,” said Brett Vokey, CEO of BreatheSuite. “We are excited to draw upon his background in commercial healthcare as we continue to work toward improving the lives of respiratory patients worldwide. Brad has exactly the experience we need to navigate the digital health ecosystem.”
 
Before working as an advisor to healthcare organizations, entrepreneurs, and other participants in healthcare, Fluegel was most recently the senior vice president and chief healthcare commercial market development officer for Walgreen Co., based in Deerfield, Ill. He was responsible for all commercial healthcare activities, including sales and contracting, biopharma relationships, retail clinics, clinical affairs, new service development and market planning. Previously, he was chief strategy and business development officer for Walgreens, responsible for corporate strategy and business development.
 
Before joining Walgreens, Fluegel served as an executive in residence at Health Evolution Partners. Before that he was executive vice president and chief strategy and external affairs officer of Wellpoint (now Anthem), among the nation’s largest health benefits companies. While at Wellpoint, Fluegel was responsible for long-term strategic planning, government affairs, corporate communications including public relations, corporate marketing, corporate development, international expansion, innovation and new business ventures.
 
Fluegel was senior vice president of national accounts and vice president, enterprise strategy at Aetna Inc. In this role, he led the national accounts business and was responsible for developing and executing on strategies that expanded Aetna’s position as a leader in the large employer market.
 
“I’m excited to join BreatheSuite, as digital healthcare has always been a passion of mine because of its ability to improve people’s lives,” said Fluegel. “I look forward to using my experience to help BreatheSuite achieve its mission to provide better, more transparent care for all people with asthma or COPD.”
 
Fluegel is well versed in the complexities of business and healthcare and is also a lecturer at the University of Pennsylvania’s Wharton School of Business. He earned a master’s degree in public policy from Harvard University’s Kennedy School of Government and a bachelor of arts degree in business administration from the University of Washington. He serves on the Board of Directors of MJHS Health System in New York City, Performant Financial Corporation, and Premera Blue Cross, among others. He was also on the board of Fitbit before its sale to Google in early 2021.
 
Fluegel’s appointment to BreatheSuite’s Board of Directors comes on the heels of BreatheSuite’s Chief Scientific Officer, Dr. Meshari F. Alwashmi, joining the Forbes Technology Council. 
 
BreatheSuite is a Canadian connected health company that developed a smart inhaler sensor designed to track and train proper inhaler usage and an app that gamifies getting asthma and COPD under control. BreatheSuite works with partners across North America to deliver better care to people with chronic respiratory conditions.